Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 63 PB Ratio is 0.80 as of Jul. 15, 2026, which is 13% above its 10-year median of 0.71. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.14 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks better than 82.54% on this metric.
The historical rank and industry rank for Wakamoto Pharmaceutical Co's PB Ratio or its related term are showing as below:
TSE:4512'
s PB Ratio Range Over the Past 10 Years
Min: 0.5 Med: 0.71 Max: 1.9
Current: 0.81
During the past 13 years, Wakamoto Pharmaceutical Co's highest PB Ratio was 1.90. The lowest was 0.50. And the median was 0.71.
TSE:4512's PB Ratio is ranked better than 82.54% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs TSE:4512: 0.81
During the past 12 months, Wakamoto Pharmaceutical Co's average Book Value Per Share Growth Rate was 3.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Wakamoto Pharmaceutical Co was 5.40% per year. The lowest was -6.90% per year. And the median was -0.05% per year.
Back to Basics: PB Ratio
Wakamoto Pharmaceutical Co (TSE:4512) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Wakamoto Pharmaceutical Co PB Ratio Related Terms
Wakamoto Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Wakamoto Pharmaceutical Co (TSE:4512) has a PB Ratio of 0.80 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is 13% above median its historical median of 0.71. Over the past decade, Wakamoto Pharmaceutical Co's PB Ratio has ranged from 0.50 to 1.90. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #161 out of 922 companies in the Drug Manufacturers industry, placing it in the top 17.5%.
Is Wakamoto Pharmaceutical Co's PB Ratio too high?
Wakamoto Pharmaceutical Co's current PB Ratio of 0.80 is 13% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 1.90. The Drug Manufacturers industry median PB Ratio is 1.92. Wakamoto Pharmaceutical Co's value of 0.80 is 58.3% below this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #161 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #161 out of 922 companies for PB Ratio. This places Wakamoto Pharmaceutical Co in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.92. Wakamoto Pharmaceutical Co's value of 0.80 is 58.3% below this benchmark. Historically, Wakamoto Pharmaceutical Co's own PB Ratio has ranged from 0.50 to 1.90 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 1.92, Wakamoto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current PB Ratio of 0.80 is 58.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current PB Ratio is 0.80, which is 13% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.14, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current PB Ratio is 0.80, which is 13% above median its 10-year median of 0.71 and 58.3% below the Drug Manufacturers industry median of 1.92. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current PB Ratio is 0.80 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.14.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
PB Ratio: 0.80 (13% above median its 10-year median of 0.71)
GF Value™: 円319.14 vs. price of 円278.00 (12.9% below fair value)
Industry Position: 58.3% below the Drug Manufacturers median (#161 of 922)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
